A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01)
Latest Information Update: 22 Feb 2025
Price :
$35 *
At a glance
- Drugs Sigvotatug vedotin (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Seagen
- 06 Feb 2025 Planned number of patients changed from 600 to 560.
- 17 Sep 2024 According to Trial design presented at the 49th European Society for Medical Oncology Congress, Enrollment has begun in the US and the EU and is planned for other regions, including APAC and LATAM.
- 17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress